FierceBiotech

New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis

INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...
FiercePharma

New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research

INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its ...
FiercePharma

Research Suggests FORTEO® Significantly Increases Bone Strength

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...
Ibj.com

Lilly wins new approval for Forteo-WEB ONLY

Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today. Lilly can now promote Forteo as a therapy for men and women ...
AOL

Does Medicare cover Forteo, and how much does it cost?

Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...